JP2010526069A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526069A5 JP2010526069A5 JP2010506316A JP2010506316A JP2010526069A5 JP 2010526069 A5 JP2010526069 A5 JP 2010526069A5 JP 2010506316 A JP2010506316 A JP 2010506316A JP 2010506316 A JP2010506316 A JP 2010506316A JP 2010526069 A5 JP2010526069 A5 JP 2010526069A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- hetero
- compound
- cyclo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000003118 aryl group Chemical group 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000005842 heteroatom Chemical group 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 8
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 102000009389 Prostaglandin D receptors Human genes 0.000 claims 5
- 108050000258 Prostaglandin D receptors Proteins 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 208000000094 Chronic Pain Diseases 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 206010010741 Conjunctivitis Diseases 0.000 claims 3
- 208000011231 Crohn disease Diseases 0.000 claims 3
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 206010028735 Nasal congestion Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010037660 Pyrexia Diseases 0.000 claims 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 3
- 208000007536 Thrombosis Diseases 0.000 claims 3
- 206010052779 Transplant rejections Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 206010052568 Urticaria chronic Diseases 0.000 claims 3
- 208000036142 Viral infection Diseases 0.000 claims 3
- 201000010105 allergic rhinitis Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 201000008937 atopic dermatitis Diseases 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000005547 chronic conjunctivitis Diseases 0.000 claims 3
- 208000037976 chronic inflammation Diseases 0.000 claims 3
- 208000024376 chronic urticaria Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 238000011010 flushing procedure Methods 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims 2
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 2
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims 2
- 125000006532 (C3-C5) alkyl group Chemical group 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000004474 heteroalkylene group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229940124003 CRTH2 antagonist Drugs 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 229940124748 beta 2 agonist Drugs 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 229960000265 cromoglicic acid Drugs 0.000 claims 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 0 **c1c(CCCCC2)c2c(*)c(*)c1*C1=CC=CI(CI*)=C1 Chemical compound **c1c(CCCCC2)c2c(*)c(*)c1*C1=CC=CI(CI*)=C1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92754507P | 2007-05-02 | 2007-05-02 | |
| US60/927,545 | 2007-05-02 | ||
| PCT/US2008/005611 WO2008137027A2 (en) | 2007-05-02 | 2008-05-01 | Compounds as crth2 and/or pgd2 receptors modulators and their use for treating asthma and allergic inflammation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010526069A JP2010526069A (ja) | 2010-07-29 |
| JP2010526069A5 true JP2010526069A5 (enExample) | 2011-06-16 |
| JP5537417B2 JP5537417B2 (ja) | 2014-07-02 |
Family
ID=39619158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506316A Expired - Fee Related JP5537417B2 (ja) | 2007-05-02 | 2008-05-01 | Ｃｒｔｈ２及び／又はｐｇｄ２受容体調節物質としての化合物、並びにぜん息及びアレルギー性炎症を治療するためのその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7960567B2 (enExample) |
| EP (1) | EP2164828B1 (enExample) |
| JP (1) | JP5537417B2 (enExample) |
| AU (1) | AU2008248201B2 (enExample) |
| CA (1) | CA2685215C (enExample) |
| ES (1) | ES2402987T3 (enExample) |
| MX (1) | MX2009011412A (enExample) |
| WO (1) | WO2008137027A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090111847A (ko) * | 2007-01-19 | 2009-10-27 | 아디아 바이오사이언스즈 인크. | Ｍｅｋ 억제제 |
| ES2471919T3 (es) * | 2007-12-19 | 2014-06-27 | Amgen, Inc | Derivados de ácido fenilac�tico como moduladores de inflamación |
| BRPI0907364A2 (pt) | 2008-02-01 | 2015-07-14 | Amira Pharmaceuticals Inc | Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina |
| WO2009102893A2 (en) | 2008-02-14 | 2009-08-20 | Amira Pharmaceuticals, Inc. | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors |
| JP2011513242A (ja) | 2008-02-25 | 2011-04-28 | アミラ ファーマシューティカルズ，インク． | プロスタグランジンｄ２受容体アンタゴニスト |
| US8426449B2 (en) | 2008-04-02 | 2013-04-23 | Panmira Pharmaceuticals, Llc | Aminoalkylphenyl antagonists of prostaglandin D2 receptors |
| CN103450138B (zh) | 2008-06-25 | 2015-04-08 | 阵列生物制药公司 | 制备6-取代的苯氧基色满羧酸衍生物的中间体 |
| US8071807B2 (en) | 2008-07-03 | 2011-12-06 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
| US8138208B2 (en) * | 2008-07-15 | 2012-03-20 | Hoffmann-La Roche Inc. | Aminotetrahydroindazoloacetic acids |
| EP2307382B1 (en) * | 2008-07-15 | 2011-12-21 | F. Hoffmann-La Roche AG | Aminotetrahydroindazoloacetic acids |
| GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| WO2010039977A2 (en) | 2008-10-01 | 2010-04-08 | Amira Pharmaceuticals, Inc. | Heteroaryl antagonists of prostaglandin d2 receptors |
| WO2010042652A2 (en) | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
| GB2465062B (en) | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
| US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
| CN102325767B (zh) * | 2008-12-22 | 2014-05-14 | 阵列生物制药公司 | 7-苯氧基色满羧酸衍生物 |
| PE20120008A1 (es) | 2009-01-12 | 2012-01-24 | Icagen Inc | Derivados de fenoxi bencenosulfonamida |
| EP2461809A4 (en) | 2009-07-31 | 2013-06-19 | Panmira Pharmaceuticals Llc | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES |
| US8815917B2 (en) | 2009-08-05 | 2014-08-26 | Panmira Pharmaceuticals, Llc | DP2 antagonist and uses thereof |
| WO2011116277A1 (en) * | 2010-03-19 | 2011-09-22 | Oxygen Biotherapeutics, Inc. | Perfluorocarbon eye cream formulations |
| JP5872552B2 (ja) | 2010-07-09 | 2016-03-01 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化学化合物 |
| US8513309B2 (en) | 2010-10-01 | 2013-08-20 | Oxygen Biotherapeutics, Inc. | Perfluorocarbons for use in treating pruritus |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| US8471030B2 (en) | 2010-12-06 | 2013-06-25 | Orochem Technologies Inc. | Purification of montelukast using simulated moving bed |
| CN103204825B (zh) | 2012-01-17 | 2015-03-04 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途 |
| CN104507930B (zh) * | 2012-06-29 | 2017-10-10 | 贝达药业股份有限公司 | 作为c‑Met酪氨酸激酶抑制剂的新型稠合吡啶衍生物 |
| TWI520962B (zh) | 2012-06-29 | 2016-02-11 | As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives | |
| AR091731A1 (es) * | 2012-07-19 | 2015-02-25 | Merck Sharp & Dohme | Antagonistas del receptor de mineralocorticoides |
| CN104870422B (zh) * | 2012-10-31 | 2019-03-15 | 富士胶片富山化学株式会社 | 胺衍生物或其盐 |
| RU2506259C1 (ru) * | 2012-12-04 | 2014-02-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославский государственный университет им. П.Г. Демидова" | Способ получения 4-{4-амино-2-хлоро-5-[(5-хлоро-2-метил-1н-бензимидазол-6-ил)амино]фенокси}бензойной кислоты |
| CN103910682B (zh) * | 2013-11-28 | 2016-03-02 | 大连理工大学 | 一种基于邻苯二胺环化的苯并咪唑类化合物制备方法 |
| AU2016236669B2 (en) * | 2015-03-24 | 2018-11-08 | Shanghai Yingli Pharmaceutical Co., Ltd | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof |
| AU2020311940A1 (en) | 2019-07-11 | 2022-02-03 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0753725B2 (ja) * | 1987-10-08 | 1995-06-07 | 富山化学工業株式会社 | ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤 |
| JPH0283376A (ja) * | 1988-09-19 | 1990-03-23 | Pfizer Pharmaceut Co Ltd | ベンゾオキサゾロン誘導体および抗アレルギー又は抗炎症組成物 |
| US5849780A (en) * | 1992-01-30 | 1998-12-15 | Sanofi | 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| US5545669A (en) * | 1994-06-02 | 1996-08-13 | Adams; Jerry L. | Anti-inflammatory compounds |
| US5929250A (en) * | 1997-01-23 | 1999-07-27 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| US6297239B1 (en) * | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| JP2002506851A (ja) * | 1998-03-13 | 2002-03-05 | メルク フロスト カナダ アンド カンパニー | カルボン酸類およびアシルスルホンアミド類、そのような化合物を含む組成物ならびに治療方法 |
| JP2000026430A (ja) * | 1998-07-02 | 2000-01-25 | Taisho Pharmaceut Co Ltd | ２、５、６−置換ベンズイミダゾール化合物誘導体 |
| HK1044532A1 (zh) * | 1999-03-01 | 2002-10-25 | 辉瑞产品公司 | 用作甲状腺受体配体的草氨酸及衍生物 |
| EP1255750A1 (en) | 2000-02-01 | 2002-11-13 | Millenium Pharmaceuticals, Inc. | INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa |
| EP1347959A1 (de) * | 2000-12-27 | 2003-10-01 | Bayer Aktiengesellschaft | Indol-derivate |
| JP2004531479A (ja) * | 2001-02-08 | 2004-10-14 | カロ バイオ アクチェブラーグ | 甲状腺受容体リガンドとしてのフェノキシ置換されたベンゾ縮合ヘテロアリール誘導体 |
| GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| PE20040844A1 (es) * | 2002-11-26 | 2004-12-30 | Novartis Ag | Acidos fenilaceticos y derivados como inhibidores de la cox-2 |
| PL377314A1 (pl) * | 2002-12-20 | 2006-01-23 | Amgen Inc. | Modulatory astmy i zapaleń na tle alergicznym |
| WO2005010202A2 (en) * | 2003-07-16 | 2005-02-03 | Ligand Pharmacueticals Incorporated | PHENYL ACETIC ACID DERIVATIVES AS HEPATOCYTE NUCLEAR FACTOR 4α (HNF-4α) MODULATOR COMPOUNDS |
| SE0302232D0 (sv) * | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
| ES2314444T3 (es) * | 2003-08-29 | 2009-03-16 | Pfizer Inc. | Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos. |
| ATE386715T1 (de) | 2003-11-25 | 2008-03-15 | Lilly Co Eli | Modulatoren des peroxisomproliferatoraktivierten rezeptors |
-
2008
- 2008-04-30 US US12/113,121 patent/US7960567B2/en active Active
- 2008-05-01 MX MX2009011412A patent/MX2009011412A/es active IP Right Grant
- 2008-05-01 AU AU2008248201A patent/AU2008248201B2/en not_active Ceased
- 2008-05-01 WO PCT/US2008/005611 patent/WO2008137027A2/en not_active Ceased
- 2008-05-01 EP EP08743426A patent/EP2164828B1/en active Active
- 2008-05-01 ES ES08743426T patent/ES2402987T3/es active Active
- 2008-05-01 CA CA2685215A patent/CA2685215C/en not_active Expired - Fee Related
- 2008-05-01 JP JP2010506316A patent/JP5537417B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010526069A5 (enExample) | ||
| JP6193922B2 (ja) | ハロアルキルヘテロアリールベンズアミド化合物 | |
| TWI382984B (zh) | 雜環化合物 | |
| JP6861703B2 (ja) | Ｔｇｒ５修飾物質およびその使用方法 | |
| JP2009521399A5 (enExample) | ||
| CA2511214A1 (en) | Asthma and allergic inflammation modulators | |
| JP2019504899A5 (enExample) | ||
| JP2015503505A5 (enExample) | ||
| JP2005507947A (ja) | ナフチリジン誘導体、その製造およびそのホスホジエステラーゼイソ酵素４（ｐｄｅ４）阻害剤としての使用 | |
| TW200530195A (en) | Benzimidazole derivatives: preparation and pharmaceutical applications | |
| JP2010510231A (ja) | アンドロゲン受容体モジュレータとしてのテトラヒドロペンタ［ｂ］インドール化合物 | |
| JP2010501478A5 (enExample) | ||
| JP6428763B2 (ja) | アミド化合物 | |
| JP2023538018A (ja) | ネトーシスの処置及び／又は予防における使用のための方法及び化合物 | |
| JP2008546770A5 (enExample) | ||
| JP2013528656A5 (enExample) | ||
| WO2022120118A1 (en) | Novel ripk1 kinase targeting protacs and methods of use thereof | |
| BRPI0615690B1 (pt) | compostos heterocíclicos de hidroxamato, seus usos e composição farmacêutica | |
| JP2018508513A5 (enExample) | ||
| JP2011519845A5 (enExample) | ||
| JP2017509611A5 (enExample) | ||
| JP6892968B2 (ja) | Ｕｒａｔ１阻害剤の結晶形及びその製造方法 | |
| JP2024526849A5 (enExample) | ||
| JP2010535156A (ja) | ウイルスポリメラーゼ阻害剤 | |
| WO2007062678A1 (en) | Phenoxyacetic acid derivatives as crth2 receptor ligands |